Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Helix
  4. Systemic Milieu Reset Protocols

Systemic Milieu Reset Protocols

Plasmapheresis and plasma-mimetic therapies to rebalance pro- and anti-aging factors.
Back to HelixView interactive version

Systemic milieu reset protocols are clinical treatment programs that combine therapeutic plasma exchange (removing and replacing blood plasma), albumin replacement, and young-plasma mimetic infusions (solutions that mimic the composition of young blood plasma) to dilute pro-aging circulating factors (substances in the blood that promote aging) and restore regenerative signaling (biological signals that promote tissue repair and regeneration). These systemic interventions aim to reset the body's internal environment to a more youthful state, potentially improving cognition, cardiovascular health, and frailty metrics without requiring chronic drug exposure, representing a comprehensive approach to addressing aging at the systemic level. Clinics and research institutions are developing these protocols.

This innovation addresses research suggesting that factors in the blood change with age and contribute to aging, where resetting the blood composition could potentially have rejuvenating effects. By combining multiple approaches to modify the blood environment, these protocols aim to create comprehensive systemic effects. However, the scientific basis and effectiveness remain areas of active research.

The technology is being explored for longevity applications, where systemic interventions could potentially address multiple aspects of aging simultaneously. As research progresses, these protocols could become more established. However, ensuring safety, demonstrating effectiveness, and managing costs remain challenges. The technology represents an interesting approach to anti-aging interventions, but requires continued research to establish efficacy and safety. Success could provide new options for healthy aging, but the scientific basis needs further validation and the approach must be carefully evaluated for safety and effectiveness.

TRL
4/9Formative
Impact
4/5
Investment
4/5
Category
Applications

Related Organizations

Alkahest logo
Alkahest

United States · Company

95%

Biotech company identifying proteins in plasma that change with age to develop targeted therapies.

Developer
Grifols logo
Grifols

Spain · Company

95%

Global healthcare company and producer of plasma-derived medicines.

Developer
UC Berkeley logo
UC Berkeley

United States · University

95%

Home to the Conboy Lab (Irina and Michael Conboy).

Researcher
Lyfspn logo
Lyfspn

United States · Startup

90%

Organization founded by Dr. Dobri Kiprov focusing on therapeutic plasma exchange for longevity.

Deployer
Stanford University logo
Stanford University

United States · University

90%

The Vuckovic Group develops inverse-designed photonics for quantum frequency conversion.

Researcher
Global Apheresis

United States · Company

85%

Clinical center specializing in therapeutic apheresis and immunopheresis.

Deployer
Elevian logo
Elevian

United States · Startup

80%

Developing medicines that restore youthful regenerative capacity, focusing on GDF11.

Developer
Young Blood Institute logo
Young Blood Institute

United States · Nonprofit

80%

A non-profit corporation researching new uses for Therapeutic Plasma Exchange.

Researcher
Fountain Therapeutics

United States · Startup

75%

Uses AI to identify cellular age reversal therapeutics.

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Connections

Applications
Applications
Blood Plasma Exchange Networks

Regional clinics offering therapeutic plasma exchange for aging biomarkers.

TRL
6/9
Impact
4/5
Investment
4/5
Applications
Applications
Partial Reprogramming Therapies

Transient expression of Yamanaka factors targeting aging phenotypes.

TRL
4/9
Impact
5/5
Investment
5/5
Applications
Applications
Immune System Rejuvenation Therapies

Interventions targeting thymic involution and clonal hematopoiesis in aging.

TRL
4/9
Impact
5/5
Investment
3/5
Applications
Applications
Cellular Rejuvenation via Epigenetic Editing

Targeted editors restoring youthful epigenetic patterns.

TRL
5/9
Impact
5/5
Investment
4/5
Applications
Applications
Precision Longevity Interventions

Personalized stacks of therapeutics and lifestyle modifications.

TRL
7/9
Impact
4/5
Investment
4/5
Applications
Applications
Senolytics for Aging

Drug programs clearing senescent cells to delay multi-system decline.

TRL
5/9
Impact
5/5
Investment
4/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions